Roberto Soria
Psychiatry · Cincinnati, OHNPI 1417020819
Payments from drug & device makers
Across 160 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$870
- Otsuka America Pharmaceutical, Inc.$582
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$459
- Ironshore Pharmaceuticals Inc.$456
- Sunovion Pharmaceuticals Inc.$403
- plus $333 from 9 others
What the payments were for
- Food & beverage$4,20297%
- Education$1333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,232 |
| Teva Pharmaceuticals USA, Inc. | 9 | $870 |
| Otsuka America Pharmaceutical, Inc. | 14 | $582 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $459 |
| Ironshore Pharmaceuticals Inc. | 2 | $456 |
| Sunovion Pharmaceuticals Inc. | 24 | $403 |
| Axsome Therapeutics, Inc. | 2 | $113 |
| Indivior Inc. | 6 | $102 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Braeburn Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Orexo US, Inc. | 1 | $11 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$611
- Jornay PM 20mg capsules (Bottle of 100)$447
- VRAYLAR$372
- CAPLYTA$251
- ABILIFY MAINTENA$237
- Austedo XR$129
- ABILIFY ASIMTUFII$123
- REXULTI$120
How this compares
$4,335 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 48 | $8,135 |
| Aripiprazole | 28 | $1,208 |
| Quetiapine Fumarate | 18 | $544 |
| Duloxetine Hcl | 14 | $367 |
| Escitalopram Oxalate | 26 | $354 |
| Clonazepam | 66 | $353 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $189 |
| Risperidone | 12 | $182 |
| Gabapentin | 13 | $105 |
| Clonidine Hcl | 16 | $88 |
| Trazodone Hcl | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cincinnati
- Henry NasrallahCincinnati$3.8M
- Caleb AdlerCincinnati$2M
- Paul KeckCincinnati$739K
- Peter BoxerCincinnati$718K
- Tracey SkaleCincinnati$674K
- Lesley ArnoldCincinnati$620K
- Stephen PolandCincinnati$440K
- Fabiano NeryCincinnati$391K
- Jeffrey StrawnCincinnati$336K
- Helen FarrellCincinnati$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.